MediDash

Reimbursement Clock

FDA approval is when a product is allowed to sell; reimbursement is when it actually can. The milestones that drive the revenue ramp are buried in 1,000-page federal rules, and companies press-release their wins, never their losses.

Source: CMS MAC Implementation File 8, FY 2027 IPPS Final Rule (corrected). CMS data as of October 1, 2026. Ownership checked October 3, 2026.

Technologies by status

The rule cycle

Technologies

Methods

Status
New begins NTAP on October 1. Continued is still receiving. Lost is no longer receiving; the maximum payment shown for a lost technology is the prior year's.
Implied cost per case
Maximum add-on payment divided by the NTAP rate. The rate is 65% as standard, and 75% for QIDP antimicrobials and the Casgevy and Lyfgenia sickle cell gene therapies. As a check, Casgevy backs out to $2.2M and Lyfgenia to $3.1M, matching their list prices. It is an implied figure, not a price. Dollar amounts are rounded to the whole dollar.
Tickers
A ticker is shown only after the company-to-ticker mapping has been verified. A dash means the ticker is withheld until it is. Ownership is re-checked every rule cycle, because products change hands.
CPT Category III
Category III codes take effect six months after release: a January release is effective July 1, and a July release is effective January 1. Source: AMA Category III semi-annual early release schedule.